False Claims Act Recoveries Reach $6.8 Billion As Lab Settles

DOJ reported a record $6.8 billion in False Claims Act recoveries for fiscal year 2025, then announced a $9.8 million Florida lab settlement days later. The developments highlight continued scrutiny of health care billing, referrals, and lab compensation practices.

False Claims Act Recoveries Reach $6.8 Billion As Lab Settles
Type
Child
Status
Approved
Title (YouTube)
Images Failed (Social)
Do not index
Publish Date (TikTok)
Videos Post IDs (Social)
Hashtags (Social)
Caption
Caption X
Cover
false-claims-act-recoveries-lab-settlement.png
OG Image
false-claims-act-recoveries-lab-settlement.png
Alt Image Text
Flat vector illustration of False Claims Act recoveries and lab settlement in healthcare, showing a laboratory, billing documents, money, and federal enforcement symbols.
Images
Videos
Publish Date (Social)
Scheduled (Social)
Scheduled (Social)
Images Posted (Social)
Images Posted (Social)
Videos Posted (Social)
Featured
Created time
Jul 24, 2026 01:33 PM
Sub-item
Authors
CTA Practice Area (Social)
TikTok Failed (Social)
Videos Post Links (Social)
TikTok Post Links (Social)
Images Post IDs (Social)
YT Post ID
Video Pending Manual (Social)
TikTok Posted (Social)
TikTok Post IDs (Social)
Video Cover (Social)
Images Post Links (Social)
First Comment (Social)
Videos Failed (Social)
YT Embedded
Images Delete (Social)
Videos Delete (Social)
Carousel Video URL (Social)
The Justice Department says False Claims Act settlements and judgments exceeding $6.8 billion in fiscal year 2025 marked the largest annual haul in the statute’s history, with the announcement released on January 16, 2026. Then, on July 20, 2026, DOJ announced that a $9,813,260 Florida laboratory settlement had resolved allegations involving referral-related compensation arrangements at NeoGenomics Laboratories Inc.
Taken together, the two developments offer a clear snapshot of where federal civil fraud enforcement stands in mid-2026: health care remains the center of gravity, whistleblower filings continue to climb, and laboratory billing and referral practices remain under close review. For readers who have followed our earlier coverage of recent litigation involving a major lab company, this latest settlement adds another reminder that laboratories face legal exposure from very different directions at the same time.

Background On The False Claims Act

The False Claims Act is a Civil War-era anti-fraud law that lets the federal government pursue entities or individuals accused of knowingly seeking money from the United States through false claims or knowingly avoiding money owed to the government. DOJ describes the statute’s treble-damages and penalty framework as one of its primary tools for protecting federal programs, including Medicare, Medicaid, TRICARE, procurement contracts, grants, and customs enforcement.
In practical terms, many FCA cases involve health care reimbursement. According to DOJ, more than $5.7 billion of the fiscal year 2025 recoveries came from matters tied to the health care industry. The same announcement also said 1,297 qui tam lawsuits were filed in fiscal year 2025, another annual record, while the government opened 401 investigations.
That whistleblower trend matters because FCA enforcement often begins with insiders. Under the law’s qui tam provisions, private relators can file suits on behalf of the government and may receive a share of a successful recovery. DOJ said successful whistleblowers typically receive 15% to 30% of the recovery, which helps explain why compliance questions inside billing-heavy industries often turn into litigation risk.

What DOJ Alleged In The Florida Lab Settlement

In the July 20, 2026 resolution, DOJ said NeoGenomics’ $9.8 million settlement addressed allegations that the company provided below-fair-market-value consulting services to some health care providers that referred testing business to the lab. The government also alleged that payments to independent consultants varied in part with referral volume or value.
Those allegations matter because DOJ tied them not only to the FCA, but also to the Anti-Kickback Statute and the Stark Law theories described in the settlement announcement. In general terms, kickback and physician-referral restrictions often become the foundation for FCA exposure when claims submitted to federal health care programs are alleged to be tainted by improper financial relationships.
DOJ also said NeoGenomics self-disclosed the conduct and received cooperation credit. The agency’s announcement stated that the company took remedial measures, including ending the consulting agreements at issue and terminating responsible employees. As in most civil fraud settlements, DOJ noted that the resolved claims remain allegations only and involve no determination of liability.

Why Laboratories Keep Appearing In FCA Enforcement

Labs occupy a complicated legal and operational space. They sit between ordering providers, payors, and patients, often with high-volume federal reimbursement streams and complicated marketing arrangements. That structure can create recurring scrutiny around referral incentives, medical necessity, test utilization, sales practices, and reimbursement coding.
DOJ’s broader fiscal year 2025 summary reinforces that point. The department said health care fraud remained a leading source of FCA recoveries, and its fact sheet shows enforcement activity spanning managed care, medically unnecessary care, pandemic-era billing, customs fraud, procurement issues, and cybersecurity-related claims. In the health care space alone, the government highlighted resolutions involving laboratories, providers, insurers, and pharmaceutical companies in the fiscal year 2025 fact sheet.
That breadth helps explain why a laboratory’s legal risk profile rarely turns on a single issue. A company may face questions about privacy or data handling in one matter and reimbursement or referral relationships in another. In that sense, this story also fits alongside our previous reporting on separate legal pressure involving another national lab operator, even though the underlying allegations are very different.

Key Implications For Providers, Whistleblowers, And Businesses

Health Care Providers

For hospitals, physician groups, and specialty practices that interact with outside labs, the NeoGenomics settlement is another sign that “free” or discounted operational support can raise difficult questions when referrals are part of the relationship. Fair-market-value analysis, consultant compensation structures, and referral-linked business development arrangements often become central facts in these cases.

Whistleblowers

The record number of qui tam filings in fiscal year 2025 suggests employees, contractors, and competitors continue to bring allegations forward at a rapid pace. People who have seen unusual commission models, lab-marketing practices, or referral-linked consulting arrangements may view DOJ’s announcements as evidence that these theories remain active enforcement priorities.

Companies That Self-Disclose

The NeoGenomics matter also highlights a different theme: DOJ expressly acknowledged cooperation and self-disclosure credit in the July 20 settlement. Some companies in similar situations may see that as a sign that early internal investigation and structured disclosure can affect the government’s resolution approach, even when the financial outcome remains significant.

What Affected Parties Might Consider

For organizations that bill federal health care programs, one takeaway is that FCA exposure often grows out of business relationships, not only claim forms. Consulting deals, independent contractor agreements, referral-development arrangements, and below-market service offerings can all become part of the government’s theory if they are seen as influencing federally reimbursed referrals.
For employees or former employees, these announcements may prompt questions about whether suspicious practices are isolated mistakes, systemic billing issues, or part of a compensation model tied to federally reimbursed business. An attorney might help evaluate whether the facts point toward a potential whistleblower claim, an employment issue, or another form of civil exposure.
For companies already under scrutiny, timing can matter. Records involving valuations, contracts, commissions, referrals, and internal communications often shape what regulators and litigants focus on first. In many matters, parties look for counsel with demonstrable experience in highly similar FCA, Anti-Kickback Statute, Stark Law, and health care fraud investigations because the overlap between those regimes can be technical and fact-specific.
Visit ReferU.AI to get matched with an attorney who has demonstrable experience in cases like yours — for free.